Comparative investigations on the bioavailability of cefuroxime axetil.
In a three-way cross-over study the bioavailability of cefuroxime was determined in 12 healthy volunteers after oral administration of 250 mg as cefuroxime axetil (Elobact; CAS 64544-07-6) in a plain aqueous suspension and as tablets from different batches. The tablet formulations showed nearly identical pharmacokinetic parameters and were bioequivalent. The mean maximum serum concentration was 4.7 micrograms/ml, achieved after 2.1 h. The serum half-live was 1.2-1.4 h, the area under the serum concentration-time curve was 14.3-14.4 micrograms/ml.h and the urinary recovery of unchanged cefuroxime was 54%. The bioavailability of cefuroxime after administration of cefuroxime axetil in aqueous suspension was lower, but bio-inequivalence was not demonstrated.
Kees
F
F
Lehrstuhl für Pharmakologie, Universität Regensburg, Straubing, Fed. Rep. of Germany.
Lukassek
U
U
Naber
K G
KG
Grobecker
H
H
D000328:Adult; D001682:Biological Availability; D002444:Cefuroxime / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006207:Half-Life; D006801:Humans; D007202:Indicators and Reagents; D008297:Male; D013535:Suspensions; D013607:Tablets
D007202:Indicators and Reagents; D013535:Suspensions; D013607:Tablets; D002444:Cefuroxime; C040738:cefuroxime axetil